{
    "2021-09-03": [
        [
            {
                "time": "2023-10-15",
                "original_text": "孙飘扬回归首秀：恒瑞医药14亿重金“引进”普那布林，能否扛起业绩“大旗”？",
                "features": {
                    "keywords": [
                        "孙飘扬",
                        "恒瑞医药",
                        "普那布林",
                        "业绩"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "北向资金连续10日扫货累计加仓近460亿，药明康德、隆基股份净买入均超8亿元",
                "features": {
                    "keywords": [
                        "北向资金",
                        "药明康德",
                        "隆基股份",
                        "加仓"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "新能源"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "恒瑞医药(600276.SH)子公司HR20033片获药物临床试验批准",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "HR20033片",
                        "临床试验",
                        "批准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "恒瑞医药：药品HR20033片获临床试验批准通知书",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "HR20033片",
                        "临床试验",
                        "批准通知书"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-09-02",
                "original_text": "A股融资融券日报：两融余额增加43.73亿元（9月2日）",
                "features": {
                    "keywords": [
                        "两融余额",
                        "增加"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "市场整体"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "医药生物行业跟踪报告：创新药系列研究 PD-1/L1普药化 国内IO市场如何演绎",
                "features": {
                    "keywords": [
                        "医药生物",
                        "创新药",
                        "PD-1/L1",
                        "普药化",
                        "IO市场"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}